市場調査レポート

商品コード

過敏性腸症候群および炎症性腸疾患治療薬の世界市場

Global Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market

出版日: 2025年07月10日
発行: BCC Research
ページ情報: 英文 155 Pages
納期: 即納可能

価格

PDF & Excel (Single User License)

USD 4,650 705,823円

レポートPDFおよびExcelを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は、機能制限があるわけではありませんが、1回までとされます。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (2-5 Users)

USD 5,580 846,988円

レポートPDFおよびExcelを同一国内の5名迄にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は計5回までとされます。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,696 1,016,385円

レポートPDFおよびExcelを同一事業所に所属される方にて人数に制限なく共有ご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。印刷機能に回数制限はありませんが、印刷したもののご利用はPDFのご利用者と同一範囲内です。

PDF & Excel (Enterprise License)

USD 8,035 1,219,632円

レポートPDFおよびExcelを同一企業の全ての事業所（資本100%子会社含む）にて人数に制限なく共有ご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。印刷機能に回数制限はなく、同一企業内にて配布ご利用可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=151.79円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の過敏性腸症候群 (IBS) および炎症性腸疾患 (IBD) 治療薬の市場規模は、2025年の333億ドルから、2030年の予測期間中は9.6%のCAGRで推移し、2030年末には526億ドルに成長すると予測されています。

2025年から

北米市場は、2025年の146億米ドルから、予測期間中はCAGR 8.2%で推移し、2030年末には216億米ドルに達すると予測されています。欧州市場は、2025年の90億米ドルから、予測期間中はCAGR 10.6%で推移し、2030年末には148億米ドルに達すると予測されています。

当レポートでは、世界の過敏性腸症候群 (IBS) および炎症性腸疾患 (IBD) 治療薬の市場を調査し、市場概要、市場影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の詳細分析などをまとめています。

セグメンテーションの内訳
市場分析：疾患別
重要ポイント
過敏性腸症候群
炎症性腸疾患
市場分析：薬剤クラス別
重要ポイント
過敏性腸症候群
炎症性腸疾患
地理的内訳
市場分析：地域別
重要ポイント
北米
欧州
アジア太平洋
南米
中東・アフリカ

第7章競合情報

重要ポイント
業界構造
IBD治療薬市場の企業シェア分析
IBS治療薬市場の競合シェア分析
戦略分析

第8章 IBSおよびIBD市場における持続可能性：ESGの観点

ESG：イントロダクション
ESGリスク評価
総論

第9章付録

調査手法
出典
略語
企業プロファイル
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BAYER AG
BIOGEN
BRISTOL-MYERS SQUIBB CO.
GILEAD SCIENCES INC.
IRONWOOD
JOHNSON & JOHNSON SERVICES INC.
LILLY
MERCK & CO. INC.
PFIZER INC.
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.
UCB S.A.
Emerging Start-ups/ Market Disruptors

図表

List of Tables

Summary Table : Global IBS and IBD Therapeutics Market, by Region, Through 2030
Table 1 : Differences Between IBD and IBS
Table 2 : List of Active Clinical Trials in Phase III, 2025
Table 3 : List of Active Clinical Trials in Phase II, 2025
Table 4 : List of Active Clinical Trials in Phase I, 2025
Table 5 : Global IBS and IBD Therapeutics Market, by Disease, Through 2030
Table 6 : Global IBS Therapeutics Market, by Region, Through 2030
Table 7 : Global IBS Therapeutics Market, by Symptom Type, Through 2030
Table 8 : Global IBS-D Therapeutics Market, by Region, Through 2030
Table 9 : Global IBS-C Therapeutics Market, by Region, Through 2030
Table 10 : Global IBS-M Therapeutics Market, by Region, Through 2030
Table 11 : Inflammatory Bowel Disease Types
Table 12 : Global IBD Therapeutics Market, by Region, Through 2030
Table 13 : Global IBD Therapeutics Market, by Type, Through 2030
Table 14 : Global UC Therapeutics Market, by Region, Through 2030
Table 15 : Global CD Therapeutics Market, by Region, Through 2030
Table 16 : Global IBS Therapeutics Market, by Drug Class, Through 2030
Table 17 : Global IBS Guanylate Cyclase-C Agonists Market, by Region, Through 2030
Table 18 : Global IBS Antibiotics Market, by Region, Through 2030
Table 19 : Global IBS Laxatives Market, by Region, Through 2030
Table 20 : Global IBS Antispasmodics Market, by Region, Through 2030
Table 21 : Global Other IBS Drug Class Therapeutics Market, by Region, Through 2030
Table 22 : Global IBD Therapeutics Market, by Drug Class, Through 2030
Table 23 : Global IBD Interleukin Inhibitors Market, by Region, Through 2030
Table 24 : Global IBD Integrin Antagonists Market, by Region, Through 2030
Table 25 : Global IBD TNF Blockers Market, by Region, Through 2030
Table 26 : Global IBD JAK Inhibitors Market, by Region, Through 2030
Table 27 : Global Other IBD Drug Class Therapeutics Market, by Region, Through 2030
Table 28 : Global IBS and IBD Therapeutics Market, by Region, Through 2030
Table 29 : North American IBS and IBD Therapeutics Market, by Country, Through 2030
Table 30 : North American IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 31 : North American IBS Therapeutics Market, by Symptom Type, Through 2030
Table 32 : North American IBS Therapeutics Market, by Drug Class, Through 2030
Table 33 : North American IBD Therapeutics Market, by Type, Through 2030
Table 34 : North American IBD Therapeutics Market, by Drug Class, Through 2030
Table 35 : U.S. IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 36 : U.S. IBS Therapeutics Market, by Symptom Type, Through 2030
Table 37 : U.S. IBS Therapeutics Market, by Drug Class, Through 2030
Table 38 : U.S. IBD Therapeutics Market, by Type, Through 2030
Table 39 : U.S. IBD Therapeutics Market, by Drug Class, Through 2030
Table 40 : Canadian IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 41 : Canadian IBS Therapeutics Market, by Symptom Type, Through 2030
Table 42 : Canadian IBS Therapeutics Market, by Drug Class, Through 2030
Table 43 : Canadian IBD Therapeutics Market, by Type, Through 2030
Table 44 : Canadian IBD Therapeutics Market, by Drug Class, Through 2030
Table 45 : Mexican IBS and IBD Market, by Disease Type, Through 2030
Table 46 : Mexican IBS Therapeutics Market, by Symptom Type, Through 2030
Table 47 : Mexican IBS Therapeutics Market, by Drug Class, Through 2030
Table 48 : Mexican IBD Therapeutics Market, by Type, Through 2030
Table 49 : Mexican IBD Therapeutics Market, by Drug Class, Through 2030
Table 50 : European IBS and IBD Therapeutics Market, by Country, Through 2030
Table 51 : European IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 52 : European IBS Therapeutics Market, by Symptom Type, Through 2030
Table 53 : European IBS Therapeutics Market, by Drug Class, Through 2030
Table 54 : European IBD Therapeutics Market, by Type, Through 2030
Table 55 : European IBD Therapeutics Market, by Drug Class, Through 2030
Table 56 : U.K. IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 57 : U.K. IBS Therapeutics Market, by Symptom Type, Through 2030
Table 58 : U.K. IBS Therapeutics Market, by Drug Class, Through 2030
Table 59 : U.K. IBD Therapeutics Market, by Type, Through 2030
Table 60 : U.K. IBD Therapeutics Market, by Drug Class, Through 2030
Table 61 : German IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 62 : German IBS Therapeutics Market, by Symptom Type, Through 2030
Table 63 : German IBS Therapeutics Market, by Drug Class, Through 2030
Table 64 : German IBD Therapeutics Market, by Type, Through 2030
Table 65 : German IBD Therapeutics Market, by Drug Class, Through 2030
Table 66 : French IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 67 : French IBS Therapeutics Market, by Symptom Type, Through 2030
Table 68 : French IBS Therapeutics Market, by Drug Class, Through 2030
Table 69 : French IBD Therapeutics Market, by Type, Through 2030
Table 70 : French IBD Therapeutics Market, by Drug Class, Through 2030
Table 71 : Italian IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 72 : Italian IBS Therapeutics Market, by Symptom Type, Through 2030
Table 73 : Italian IBS Therapeutics Market, by Drug Class, Through 2030
Table 74 : Italian IBD Therapeutics Market, by Type, Through 2030
Table 75 : Italian IBD Therapeutics Market, by Drug Class, Through 2030
Table 76 : Spanish IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 77 : Spanish IBS Therapeutics Market, by Symptom Type, Through 2030
Table 78 : Spanish IBS Therapeutics Market, by Drug Class, Through 2030
Table 79 : Spanish IBD Therapeutics Market, by Type, Through 2030
Table 80 : Spanish IBD Therapeutics Market, by Drug Class, Through 2030
Table 81 : Rest of Europe IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 82 : Rest of Europe IBS Therapeutics Market, by Symptom Type, Through 2030
Table 83 : Rest of Europe IBS Therapeutics Market, by Drug Class, Through 2030
Table 84 : Rest of Europe IBD Therapeutics Market, by Type, Through 2030
Table 85 : Rest of Europe IBD Therapeutics Market, by Drug Class, Through 2030
Table 86 : Asia-Pacific IBS and IBD Therapeutics Market, by Country, Through 2030
Table 87 : Asia-Pacific IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 88 : Asia-Pacific IBS Therapeutics Market, by Symptom Type, Through 2030
Table 89 : Asia-Pacific IBS Therapeutics Market, by Drug Class, Through 2030
Table 90 : Asia-Pacific IBD Therapeutics Market, by Type, Through 2030
Table 91 : Asia-Pacific IBD Therapeutics Market, by Drug Class, Through 2030
Table 92 : Chinese IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 93 : Chinese IBS Therapeutics Market, by Symptom Type, Through 2030
Table 94 : Chinese IBS Therapeutics Market, by Drug Class, Through 2030
Table 95 : Chinese IBD Therapeutics Market, by Type, Through 2030
Table 96 : Chinese IBD Therapeutics Market, by Drug Class, Through 2030
Table 97 : Australian IBS and IBD Market, by Disease Type, Through 2030
Table 98 : Australian IBS Therapeutics Market, by Symptom Type, Through 2030
Table 99 : Australian IBS Therapeutics Market, by Drug Class, Through 2030
Table 100 : Australian IBD Therapeutics Market, by Type, Through 2030
Table 101 : Australian IBD Therapeutics Market, by Drug Class, Through 2030
Table 102 : Japanese IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 103 : Japanese IBS Therapeutics Market, by Symptom Type, Through 2030
Table 104 : Japanese IBS Therapeutics Market, by Drug Class, Through 2030
Table 105 : Japanese IBD Therapeutics Market, by Type, Through 2030
Table 106 : Japanese IBD Therapeutics Market, by Drug Class, Through 2030
Table 107 : Indian IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 108 : Indian IBS Therapeutics Market, by Symptom Type, Through 2030
Table 109 : Indian IBS Therapeutics Market, by Drug Class, Through 2030
Table 110 : Indian IBD Therapeutics Market, by Type, Through 2030
Table 111 : Indian IBD Therapeutics Market, by Drug Class, Through 2030
Table 112 : South Korean IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 113 : South Korean IBS Therapeutics Market, by Symptom Type, Through 2030
Table 114 : South Korean IBS Therapeutics Market, by Drug Class, Through 2030
Table 115 : South Korean IBD Therapeutics Market, by Type, Through 2030
Table 116 : South Korean IBD Therapeutics Market, by Drug Class, Through 2030
Table 117 : Rest of Asia-Pacific IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 118 : Rest of Asia-Pacific IBS Therapeutics Market, by Symptom Type, Through 2030
Table 119 : Rest of Asia-Pacific IBS Therapeutics Market, by Drug Class, Through 2030
Table 120 : Rest of Asia-Pacific IBD Therapeutics Market, by Type, Through 2030
Table 121 : Rest of Asia-Pacific IBD Therapeutics Market, by Drug Class, Through 2030
Table 122 : South American IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 123 : South American IBS Therapeutics Market, by Symptom Type, Through 2030
Table 124 : South American IBS Therapeutics Market, by Drug Class, Through 2030
Table 125 : South American IBD Therapeutics Market, by Type, Through 2030
Table 126 : South American IBD Therapeutics Market, by Drug Class, Through 2030
Table 127 : MEA IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 128 : MEA IBS Therapeutics Market, by Symptom Type, Through 2030
Table 129 : MEA IBS Therapeutics Market, by Drug Class, Through 2030
Table 130 : MEA IBD Therapeutics Market, by Type, Through 2030
Table 131 : MEA IBD Therapeutics Market, by Drug Class, Through 2030
Table 132 : Recent Developments in the IBS and IBD Therapeutics Market, 2022-2024
Table 133 : ESG Risk Rankings for IBS and IBD Therapeutic Companies, 2025
Table 134 : Report Information Sources
Table 135 : Abbreviations Used in the Global IBS and IBD Market
Table 136 : AbbVie Inc.: Company Snapshot
Table 137 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
Table 138 : AbbVie Inc.: Product Portfolio
Table 139 : AbbVie Inc.: News/Key Developments, 2024 and 2023
Table 140 : Amgen Inc.: Company Snapshot
Table 141 : Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 142 : Amgen Inc.: Product Portfolio
Table 143 : Amgen Inc.: News/Key Developments, 2022 and 2023
Table 144 : AstraZeneca: Company Snapshot
Table 145 : AstraZeneca: Financial Performance, FY 2023 and 2024
Table 146 : AstraZeneca: Product Portfolio
Table 147 : AstraZeneca: News/Recent Developments, 2023
Table 148 : Bayer AG: Company Snapshot
Table 149 : Bayer AG: Financial Performance, FY 2023 and 2024
Table 150 : Bayer AG: Product Portfolio
Table 151 : Bayer AG: News/Key Developments, 2024
Table 152 : Biogen: Company Snapshot
Table 153 : Biogen: Financial Performance, FY 2023 and 2024
Table 154 : Biogen: Product Portfolio
Table 155 : Biogen: News/Key Developments, 2022
Table 156 : Bristol-Myers Squibb Co.: Company Snapshot
Table 157 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 158 : Bristol-Myers Squibb Co.: Product Portfolio
Table 159 : Bristol-Myers Squibb Co.: News/Key Developments, 2022-2024
Table 160 : Gilead Sciences Inc.: Company Snapshot
Table 161 : Gilead Sciences Inc.: Financial Performance, FY 2023 and 2024
Table 162 : Gilead Sciences Inc.: Product Portfolio
Table 163 : Gilead Sciences Inc.: News/Key Developments, 2024
Table 164 : Ironwood: Company Snapshot
Table 165 : Ironwood: Financial Performance, FY 2023 and 2024
Table 166 : Ironwood: Product Portfolio
Table 167 : Ironwood: News/Key Developments, 2023
Table 168 : Johnson & Johnson Services Inc.: Company Snapshot
Table 169 : Johnson & Johnson Services Inc.: Financial Performance, FY 2023 and 2024
Table 170 : Johnson & Johnson Services Inc.: Product Portfolio
Table 171 : Johnson & Johnson Services Inc.: News/Key Developments, 2024
Table 172 : Lilly: Company Snapshot
Table 173 : Lilly: Financial Performance, FY 2023 and 2024
Table 174 : Lilly: Product Portfolio
Table 175 : Lilly: News/Key Developments, 2024
Table 176 : Merck & Co. Inc.: Company Snapshot
Table 177 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
Table 178 : Merck & Co. Inc.: Product Portfolio
Table 179 : Merck & Co. Inc.: News/Key Developments, 2023
Table 180 : Pfizer Inc.: Company Snapshot
Table 181 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 182 : Pfizer Inc.: Product Portfolio
Table 183 : Pfizer Inc.: News/Key Developments, 2024
Table 184 : Sanofi: Company Snapshot
Table 185 : Sanofi: Financial Performance, FY 2023 and 2024
Table 186 : Sanofi: Product Portfolio
Table 187 : Sanofi: News/Key Developments, 2023
Table 188 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot
Table 189 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2023 and 2024
Table 190 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 191 : Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2023
Table 192 : UCB S.A.: Company Snapshot
Table 193 : UCB S.A.: Financial Performance, FY 2023 and 2024
Table 194 : UCB S.A.: Product Portfolio
Table 195 : List of Few Emerging Startups

List of Figures

Summary Figure : Global IBS and IBD Therapeutics Market Shares, by Region, 2024
Figure 1 : Porter's Five Forces Analysis of the IBS and IBD Therapeutics Industry
Figure 2 : Global Market Dynamics of IBS and IBD Therapeutics
Figure 3 : Emerging Technologies in the IBS and IBD Therapeutics Market
Figure 4 : Global IBS and IBD Therapeutics Market Shares, by Disease, 2024
Figure 5 : Global IBS Therapeutics Market Shares, by Symptom Type, 2024
Figure 6 : Global IBD Therapeutics Market Shares, by Type, 2024
Figure 7 : Global IBS Therapeutics Market Shares, by Drug Class, 2024
Figure 8 : Global IBD Therapeutics Market Shares, by Drug Class, 2024
Figure 9 : Global IBS and IBD Therapeutics Market Shares, by Region, 2024
Figure 10 : North American IBS and IBD Therapeutics Market Shares, by Country, 2024
Figure 11 : European IBS and IBD Therapeutics Market Shares, by Country, 2024
Figure 12 : Asia-Pacific IBS and IBD Therapeutics Market Shares, by Country, 2024
Figure 13 : Company Share Analysis of IBD Therapeutics Market, 2024
Figure 14 : Company Share Analysis of IBS Therapeutics Market, 2024
Figure 15 : Key ESG Metrics of IBS and IBD Therapeutics Companies
Figure 16 : AbbVie Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 17 : AbbVie Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 18 : Amgen Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 19 : Amgen Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 20 : AstraZeneca: Revenue Shares, by Business Unit, FY 2024
Figure 21 : AstraZeneca: Revenue Shares, by Region/Country, FY 2024
Figure 22 : Bayer AG: Revenue Shares, by Business Unit, FY 2024
Figure 23 : Bayer AG: Revenue Shares, by Country/Region, FY 2024
Figure 24 : Biogen: Revenue Shares, by Business Unit, FY 2024
Figure 25 : Biogen: Revenue Shares, by Country/Region, FY 2024
Figure 26 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2024
Figure 27 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2024
Figure 28 : Gilead Sciences Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 29 : Gilead Sciences Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 30 : Ironwood: Revenue Shares, by Country/Region, FY 2024
Figure 31 : Johnson & Johnson Services Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 32 : Johnson & Johnson Services Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 33 : Lilly: Revenue Shares, by Business Unit, FY 2024
Figure 34 : Lilly: Revenue Shares, by Country/Region, FY 2024
Figure 35 : Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 36 : Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 37 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 38 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 39 : Sanofi: Revenue Shares, by Country/Region, FY 2024
Figure 40 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Business Unit, FY 2024
Figure 41 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Country/Region, FY 2024
Figure 42 : UCB S.A.: Revenue Shares, by Business Unit, FY 2024
Figure 43 : UCB S.A.: Revenue Shares, by Country/Region, FY 2024

Product Code: BIO269A

The global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics is expected to grow from $33.3 billion in 2025 and is projected to reach $52.6 billion by the end of 2030, at a compound annual growth rate (CAGR) of 9.6% during the forecast period of 2025 to 2030.

The North American market for IBS and IBD therapeutics is expected to grow from $14.6 billion in 2025 and is projected to reach $21.6 billion by the end of 2030, at a CAGR of 8.2% during the forecast period of 2025 to 2030.

The European market for IBS and IBD therapeutics is expected to grow from $9 billion in 2025 and is projected to reach $14.8 billion by the end of 2030, at a CAGR of 10.6% during the forecast period of 2025 to 2030.

Report Scope

The report provides an overview of the global irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics market and analyzes market trends. It includes global revenue ($ million) for the base year 2024, estimated data for 2025 and forecast data from 2026 through 2030. The market is segmented into irritable bowel syndrome and inflammatory bowel disease based on disease type. The IBS therapeutics segment is further segmented based on symptom type and drug class.

By symptom type, IBS therapeutics include IBS with constipation (IBS-C), IBS with diarrhea (IBS-D) and IBS with mixed symptoms (IBS-M).
By drug class, IBS therapeutics include guanylate cyclase-C agonists, antibiotics, laxatives, antispasmodics and others.

The IBD therapeutics segment is further segmented based on type and drug class.

By type, IBD therapeutics include ulcerative colitis and Crohn's disease.
By drug class, therapeutics for IBD include interleukin inhibitors, integrin antagonists, TNF inhibitors, JAK (Janus kinases) inhibitors, and others

The report also focuses on regional market segmentation. The regions covered in this study include North America, Europe, Asia-Pacific, South America and the Middle East and Africa (MEA), focusing on significant countries in these regions. The report includes an analysis of the competitive landscape, which provides the ranking and share of key businesses in the global IBS and IBD therapeutics market. A dedicated section of company profiles providing details about leading market enterprises is also included.

The scope does not cover alternative therapies for IBS and IBD, such as herbal medicine, dietary supplements and behavioral therapies.

Report Includes

142 data tables and 54 additional tables
Analysis of the global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics
Analyses of global market trends, with historic revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
Estimates of the market's size and revenue prospects, along with a corresponding market share analysis by symptom type, drug class, type, and region
Facts and figures pertaining to market dynamics, technological advances, regulations and the impact of macroeconomic factors
Insights derived from Porter's Five Forces model, as well as global supply chain analysis
Patent analysis, featuring key granted and published patents
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
Profiles of the leading companies, including AbbVie Inc., Johnson & Johnson Services Inc., Ironwood Pharmaceuticals, Takeda Pharmaceuticals, and Amgen Inc.

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion

Chapter 2 Market Overview

Overview
Inflammatory Bowel Disease
Irritable Bowel Syndrome
Porter's Five Forces Analysis in the IBS and IBD Therapeutics Market
Potential of New Entrants (Low to Moderate)
Bargaining Power of Suppliers (Low)
Bargaining Power of Buyers (High)
Threat of Substitute Products (Moderate)
Industry Rivalry (High)
Impact of U.S. Tariffs
Macroeconomic Factor Analysis
Population Demographics and Aging Populations
Government Policies on Drug Prices

Chapter 3 Market Dynamics

Market Dynamics
Market Drivers
Rising Prevalence of Gastrointestinal Disorders
Increasing Entry of Biologics and Biosimilars
Market Restraints
Side Effects and Ceiling Impact of Biologics
Overlap with Other GI Disorders
Use of Alternative Treatment Approaches
Market Opportunities
Self-Administered Drugs
Personalized Therapies

Chapter 4 Regulatory Landscape

Regulatory Aspects of IBS and IBD Therapeutics
The U.S.
European Union
Asia-Pacific

Chapter 5 Emerging Technologies and Pipeline Analysis

Key Takeaways
Emerging Technologies
Novel Target-Based Small-Molecule Drugs
Microbiome-Based Therapeutics
Advanced Combination Treatments
AI for Drug Discovery
Pipeline Analysis

Chapter 6 Market Segmentation Analysis

Segmentation Breakdown
Market Analysis by Disease
Key Takeaways
Irritable Bowel Syndrome
Inflammatory Bowel Disease
Market Analysis by Drug Class
Key Takeaways
Irritable Bowel Syndrome
Inflammatory Bowel Disease
Geographic Breakdown
Market Analysis by Region
Key Takeaways
North America
Europe
Asia-Pacific
South America
Middle East and Africa

Chapter 7 Competitive Intelligence

Key Takeaways
Industry Structure
Company Share Analysis of the IBD Therapeutics Market
Competitive Share Analysis of the IBS Therapeutics Market
Strategic Analysis

Chapter 8 Sustainability in the IBS and IBD Market: An ESG Perspective

Introduction to ESG
ESG Risk Ratings
Conclusion

Chapter 9 Appendix

Methodology
Sources
Abbreviations
Company Profiles
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BAYER AG
BIOGEN
BRISTOL-MYERS SQUIBB CO.
GILEAD SCIENCES INC.
IRONWOOD
JOHNSON & JOHNSON SERVICES INC.
LILLY
MERCK & CO. INC.
PFIZER INC.
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.
UCB S.A.
Emerging Start-ups/ Market Disruptors

過敏性腸症候群および炎症性腸疾患治療薬の世界市場

Global Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market

目次

第1章エグゼクティブサマリー

第2章市場概要

第3章市場力学

第4章規制状況

第5章新興技術とパイプライン分析

第6章市場セグメンテーション分析

第7章競合情報

第8章 IBSおよびIBD市場における持続可能性：ESGの観点

第9章付録

List of Tables

List of Figures

Report Scope

Report Includes

Table of Contents

Chapter 1 Executive Summary

Chapter 2 Market Overview

Chapter 3 Market Dynamics

Chapter 4 Regulatory Landscape

Chapter 5 Emerging Technologies and Pipeline Analysis

Chapter 6 Market Segmentation Analysis

Chapter 7 Competitive Intelligence

Chapter 8 Sustainability in the IBS and IBD Market: An ESG Perspective

Chapter 9 Appendix

過敏性腸症候群および炎症性腸疾患治療薬の世界市場

Global Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market

目次

第1章 エグゼクティブサマリー

第2章 市場概要

第3章 市場力学

第4章 規制状況

第5章 新興技術とパイプライン分析

第6章 市場セグメンテーション分析

第7章 競合情報

第8章 IBSおよびIBD市場における持続可能性：ESGの観点

第9章 付録

List of Tables

List of Figures

Report Scope

Report Includes

Table of Contents

Chapter 1 Executive Summary

Chapter 2 Market Overview

Chapter 3 Market Dynamics

Chapter 4 Regulatory Landscape

Chapter 5 Emerging Technologies and Pipeline Analysis

Chapter 6 Market Segmentation Analysis

Chapter 7 Competitive Intelligence

Chapter 8 Sustainability in the IBS and IBD Market: An ESG Perspective

Chapter 9 Appendix

第1章エグゼクティブサマリー

第2章市場概要

第3章市場力学

第4章規制状況

第5章新興技術とパイプライン分析

第6章市場セグメンテーション分析

第7章競合情報

第9章付録